Probable reinfection with hepatitis C virus in a chronic hepatitis C patient with a sustained response to combination therapy

Journal of the Formosan Medical Association

Volumn 100, Issue 12, 2001, Pages 824-828

  Kao, Jia Horng ^a   Lai, Ming Yang ^a   Chen, Pei Jer ^a   Chen, Ding Shinn ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Chronic hepatitis C; Combination therapy; Genotype; Hepatitis C virus; Interferon; Reactivation; Reinfection; Ribavirin; Sustained response

Indexed keywords

ALPHA2A INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CASE REPORT; CHRONIC DISEASE; CLEARANCE; DISEASE EXACERBATION; DRUG RESPONSE; FOLLOW UP; GENE SEQUENCE; GENERAL PRACTITIONER; GENETIC ANALYSIS; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; MALE; PATIENT EDUCATION; REINFECTION; REMISSION; SEQUENCE HOMOLOGY; SUPERINFECTION; VIREMIA; VIRUS IMMUNITY; VIRUS ISOLATION; VIRUS STRAIN;

EID: 84983722798     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Hepatitis C
2. Management of hepatitis C
3. Lack of protective immunity against reinfection with hepatitis C virus
4. Immunity in hepatitis C infection
5. Superinfection of chimpanzees carrying hepatitis C virus of genotype II/1b with that of genotype III/2a or I/1a
6. Superinfection of heterologous hepatitis C virus in a patient with chronic type C hepatitis
7. Superinfection of homotypic virus in hepatitis C virus carriers: Studies on patients with posttransfusion hepatitis
8. Dynamic behavior of hepatitis C virus in chronically infected patients receiving liver graft from infected donors
9. The treatment of chronic viral hepatitis
10. Interferon alfa-2b monotherapy versus interferon alfa 2b plus ribavirin as initial treatment for chronic hepatitis C: Results of a US multi-center randomized controlled trial
11. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Therapy Group (IHIT)
12. Antiviral therapy for patients with chronic hepatitis C
13. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon therapy
14. Long-term course of interferon-treated chronic hepatitis C
15. 10-Year follow-up after interferon therapy for chronic hepatitis C
16. Prognosis of chronic hepatitis C: Results of a large, prospective cohort study
17. Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa
18. Intrafamilial transmission of hepatitis C virus: The important role of infections between spouses
19. Genotypes of hepatitis C virus in Taiwan and the progression of liver disease
20. Mixed infections of hepatitis C virus as a factor in acute exacerbation of chronic type C hepatitis
21. Absence of extensive genetic heterogeneity of hepatitis C virus in antibody-negative chronic hepatitis C
22. Molecular virology of hepatitis C virus
23. Quasispecies of hepatitis C virus and genetic drift of the hypervariable region in chronic type C hepatitis
24. Mapping of immunodominant CD4+ T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection
25. Effects of interferon treatment on the anti-viral T-cell response in hepatitis C virus genotype 1b- and 2c-infected patients
26. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C
27. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C
28. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C
29. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes
30. Hepatitis C virus serotype-specific core and NS4 antibodies in injecting drug users participating in the Amsterdam cohort studies
31. Public health challenges in hepatitis C virus infection